Plain-English translation of NCT06860711 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether ketorolac and ibuprofen—common pain-relief medications—can be safely used for a few days after surgery in children who have mild-to-moderate chronic kidney disease. Doctors want to know if this medication increases the risk of sudden kidney problems after surgery, or if it's safe to use as it normally would be.
Children with chronic kidney disease who need surgery face tough choices about pain relief, because doctors worry this medication might harm their kidneys. This study aims to answer that question so doctors can better care for these children without fear.
You likely qualify if…
You likely don't qualify if…
After your urologic surgery, you will receive either the pain-relief medication or a placebo (inactive treatment that looks and tastes the same). You'll start with an intravenous dose for up to 8 doses, then switch to liquid medication by mouth. The entire treatment period lasts no more than 5 days. Researchers will monitor you to check your kidney function and watch for any problems.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Post-approval monitoring
Sponsor
University of Colorado, Denver
Enrollment target
~164 participants
Started
July 2025
Primary completion
June 2028
Age range
18 Months – 25 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kyle Rove, MD
Children's Hospital Colorado
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.